37 results about "He Antibody" patented technology

The invention discloses a broad-spectrum monoclonal antibody for resisting porcine epidemic diarrhea virus S protein and application of the broad-spectrum monoclonal antibody. Specifically, firstly, two monoclonal antibodies GC33D8-1 and GC33A4-3 which have broad-spectrum binding characteristics with the porcine epidemic diarrhea virus S protein are obtained, the GC33D8-1 antibody has good universality and can have strong affinity with different strains, and the GC33A4-3 antibody can be bound for 3 times. Secondly, the two monoclonal antibodies are respectively used as a capture antibody and a detection antibody, a double-antibody sandwich ELISA method is established, and the double-antibody sandwich ELISA method is applied to PEDV vaccine S protein quantification, has better parallelism compared with other antibodies, and can be widely applied to detection of different strains. The method can be used for detecting semi-finished products and finished products, can be used for process establishment and optimization of porcine epidemic diarrhea virus vaccine antigens, vaccine quality evaluation and stability monitoring, has the advantages of high sensitivity, high accuracy, high repeatability and high flux, and solves the problems that broad-spectrum detection cannot be carried out at present and an S protein ELISA method only can be used for qualitative judgment.

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR12 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR12 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR12 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR12 has high affinity and dilution stability and is suitable for clinical large-dose administration.

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR75 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR75 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR75 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR75 has high affinity and dilution stability and is suitable for clinical large-dose administration.

The invention discloses a novel coronavirus neutralizing antibody GR46, a detection kit and application of the novel coronavirus neutralizing antibody GR46. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR46 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR46 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR46 to S-Trimer and RBD under 2-time and 300-time dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR46 has high affinity and dilution stability and is suitable for clinical large-dose administration.

The invention provides an anti-CDH17 antibody or an antigen binding fragment thereof, a CDH17-targeted antibody drug conjugate (ADC) and application thereof. The anti-CDH17 antibody provided by the invention can be specifically combined with CDH17 protein, and has a relatively strong CDH17 expression tumor cell killing effect, so that the anti-CDH17 antibody has high-specificity treatment application potential of CDH17 expression tumor. Furthermore, the anti-CDH17 antibody provided by the invention can be effectively internalized on CDH17 expression tumor cells, ADC formed by coupling the anti-CDH17 antibody with a small-molecule toxic compound keeps high internalization activity and strong binding capacity to target protein CDH17, and shows high killing activity to the CDH17 expression tumor cells.

The invention discloses a porcine epidemic diarrhea virus S protein monoclonal antibody and application thereof. Specifically, two monoclonal antibodies GC42G2-1 and GC33D8-1 which have broad-spectrum binding characteristics with the porcine epidemic diarrhea virus S protein are obtained firstly, the GC42G2-1 antibody has good universality and can have strong affinity with different strains, and the GC33D8-1 antibody can be used for binding the porcine epidemic diarrhea virus S protein in a broad-spectrum manner. The GC42G2-1 can be independently used, and also can be matched with a polyclonal antibody or GC33D8-1 to be used for sandwich ELISA (enzyme-linked immunosorbent assay) so as to detect and quantify PEDV (porcine epidemic diarrhea virus). Secondly, the two monoclonal antibodies are respectively used as a coating antibody and a detection antibody, a double-antibody sandwich ELISA method is established, and the double-antibody sandwich ELISA method is applied to PEDV vaccine S protein quantification, has better parallelism compared with other antibodies, and can be widely applied to detection of different strains. The method disclosed by the invention has the advantages of high sensitivity, high accuracy, high repeatability and high flux, and can be used for the development of blocking ELISA (Enzyme-Linked Immunosorbent Assay), capturing ELISA, indirect ELISA, competitive ELISA and detection of porcine epidemic diarrhea viruses by colloidal gold test strips.

This disclosure provides an anti-5T4 antigen-binding domain that can be incorporated into antibodies and receptors, including a bispecific anti-5T4 antibody, a biparatopic anti-5T4 antibody, and its antibody-drug conjugate, comprising a first antigen-binding domain that specifically binds to a first 5T4 epitope, a second antibody-antigen-binding domain that specifically binds to a second 5T4 epitope that is not identical to the first 5T4 epitope (the first antigen-binding domain is operably linked to the second antigen-binding domain), and a chemotherapeutic agent. This disclosure further provides methods for using it for the treatment of cancer.

The invention discloses an anti-human OX40 inhibitory antibody or an antigen binding fragment thereof, a preparation method and application, and belongs to the technical field of biological immunity. The EC50 of the human-mouse chimeric antibody Y07-L2 and the EC50 of the combination of the humanized antibody Y07-C2 and the human OX40, which are prepared by the invention, are close to those of a targeted antibody drug KHK-4083 for inhibiting the OX40. A heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.14, and a light chain variable region of the human-mouse chimeric antibody Y07-L2 is as shown in SEQ ID NO.15; the heavy chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.20, and the light chain variable region of the humanized antibody Y07-C2 is as shown in SEQ ID NO.21; the CDR region of the humanized antibody Y07-C2 is mutated, and the mutant antibodies Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.

The invention belongs to the technical field of biology, and particularly relates to a construction method and application of an antibody two-dimensional code. The invention creatively develops a method for generating an antibody two-dimensional code (Ab-QRcode) only based on an antibody sequence without antigen information. The antibody two-dimensional code generated by the method can describe species specificity, variety and targeting specificity information of the antibody, and each antibody has a unique two-dimensional code which is unique and different from other antibodies. Based on the two-dimensional code, the target specificity of the antibody can be distinguished, and the antibody can be clustered according to the difference between the target specificity of the antibody, so that the clustering of the antibody for identifying the same or similar antigen can be realized.

The present invention specifically relates to a monoclonal antibody 2D7, which is directed against the monkeypox virus A35R protein. The present invention first repeats and concatenates the MPXV A35S gene sequence via a linker (Gly4Ser)3, and then uses this as an immunogen to screen and obtain the monoclonal antibody 2D7, which is directed against the monkeypox virus A35R protein. The heavy chain of this monoclonal antibody comprises CDR1, CDR2, and CDR3 composed of the amino acid sequences shown in SEQ ID NOs. 1 to 3, and the light chain comprises CDR1, CDR2, and CDR3 composed of the amino acid sequences shown in SEQ ID NOs. 4 to 6. Further experimental studies have revealed that it has good specificity, high binding activity and affinity, and can be used in colloidal gold rapid detection kits, laying the foundation for the detection of monkeypox virus A35R protein.

Objective of the present invention is to provide a novel Nav1.7 monoclonal antibody. It discloses a Nav1.7 monoclonal antibody or its antibody fragment, having specific six CDRs or specific heavy chain variable regions / light chain variable regions. The monoclonal antibody and the like can be used for treating or preventing pain, pruritus and so on.

The present invention provides anti-human LILRB4 monoclonal antibodies or fragments thereof, immune checkpoint inhibitors, therapeutic agents for immune checkpoint-related diseases, and methods for measuring human LILRB4.SOLUTION: Anti-human immunosuppressive receptor LILRB4 monoclonal antibodies or fragments thereof that specifically bind to a human immunosuppressive receptor LILRB4 and inhibit binding between fibronectin and the human immunosuppressive receptor LILRB4, immune checkpoint inhibitors containing the anti-human immunosuppressive receptor LILRB4 monoclonal antibodies or fragments thereof as active ingredients, therapeutic agents for immune checkpoint-related diseases, and methods for measuring a human immunosuppressive receptor LILRB4 in a biological sample using the anti-human immunosuppressive receptor LILRB4 monoclonal antibodies or fragments thereof.SELECTED DRAWING: None

The present invention describes single domain monoclonal antibodies that specifically bind to B7H3 (also known as CD276). The single-domain monoclonal antibody comprises a camel VHH domain nano antibody and a rabbit VH domain nano antibody which are selected from a phage display library. B7H3-targeted chimeric antigen receptors (CARs) and other antibody conjugates are also described. The single-domain monoclonal antibody and the conjugate thereof can be used for diagnosing and treating solid tumors expressing B7H3.

This invention provides a recombinant Staphylococcus aureus enterotoxin B nanoparticle protein vaccine, mSEB-mi3, its preparation method, and its applications. This invention utilizes a SpyTag / SpyCather protein linker system to connect the recombinant protein to the nanoparticle protein, allowing mSEB to be displayed on the surface of self-contained nanoparticles, thus obtaining the recombinant Staphylococcus aureus enterotoxin B nanoparticle protein mSEB-mi3. Both mSEB-SpyTag and SpyCather-mi3 proteins in this invention are induced to be expressed in soluble form in Escherichia coli. The mSEB-SpyTag and SpyCather-mi3 of this invention can be covalently bound via isopeptide bonds to form the mSEB-mi3 nanoparticle protein vaccine. The binding conditions are simple, and when combined with the adjuvant MF59, it can induce rapid antibody production in mice, generating a high-level immune response and exerting a protective effect. Furthermore, its antibody response rate and protective efficiency are superior to those of the monomeric protein mSEB.

We provide camptothecin-based pharmaceuticals and their antibody conjugates. [Solution] A compound of the following formula I and its antibody complex are provided. JPEG2026086826000042.jpg62170 (In formula I, R1 and R2 are independently a C1-C3 alkyl group, -H, -CF3, aryl group, heteroaryl group, etc.)

The application discloses a novel coronavirus neutralizing antibody, a detection kit and application thereof, an amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No. 1, and an amino acid sequence of a light chain variable region is shown as SEQ ID No. 2. The application screens the affinity-matured antibody through bioinformatics analysis of a single B cell, combines single-cell RNA sequencing, VDJ rearrangement analysis and somatic hypermutation research, optimizes the antibody screening process, avoids blindness of a traditional method, and improves the accuracy and effectiveness of antibody screening. The neutralizing antibody GR58 provided by the application can specifically combine with a RBD domain of SARS-CoV-2 and a S-Trimer domain of an Omicron mutant strain through the heavy chain and light chain variable regions, realizes broad-spectrum neutralization of SARS-CoV-2 and mutant strains thereof, and the antibody GR58 is significantly superior to other antibodies in the binding activity of S-Trimer and RBD under 2-fold and 300-fold dilution conditions, indicating that the antibody has high affinity and dilution stability, and is suitable for clinical large-dose administration requirements.

The present invention belongs to the technical field of monoclonal antibody, and specifically relates to a humanized antibody against HER2 antigen and its application. A humanized antibody against HER2 antigen, wherein the amino acid sequences of complementarity determining region 1, complementarity determining region 2 and complementarity determining region 3 of the heavy chain are GYTFTSY, NTNTGN, CARRWLGYFDYW respectively; and the amino acid sequences of complementarity determining region 1, complementarity determining region 2 and complementarity determining region 3 of the light chain are QSISSYLN, AASSLQS, CQQSYSTPLTF respectively. The antibody sequence of this solution is different from other HER2 antibodies in the prior art, and the effect is consistent with that of trastuzumab. This technical solution can solve the technical problem of fewer types of antibodies against HER2 antigen in the prior art. The new antibody can overcome the problem of tumor drug resistance of a single drug, and is used for antibody combination therapy for cancer, having an ideal application and promotion prospect.

This invention provides a series of antibodies or antigen-binding fragments thereof that have high specific binding ability to tumor cells expressing the ITGA2 protein. The antibodies or antigen-binding fragments of this invention can achieve excellent killing effects against tumor cells after being conjugated with a drug to form an antibody-drug conjugate.

The present invention relates to medical uses comprising the administration of anti-human CCR8 antibodies in specifically defined dosage regimens in monotherapy or combination therapy with an anti-PD-(L)1 antibody. The dosing schemes were developed for anti-human / cynomolgus CCR8 antibody TPP-23411, but they can also be used for other antibodies having similar properties as TPP-23411. The medical uses or dosage regimens may comprise a stratification step to select patients with an increased probability of treatment success. Suggested biomarkers are a) Tumor Proportion Score or Combined Positive Score as a measure for PD-(L)1 expression, b) analysing in a blood, plasma or serum sample inflammatory cytokines and c) previous treatment of the cancer for at least 6 months with an anti-PD-(L)1 antibody. Furthermore, provided are anti-human CCR8 antibody-based medical uses and treatment methods comprising the administration of a Zr-89-labeled anti-CD8 minibody to determine the abundance and / or distribution of CD8 cells by means of a PET scan for stratification or for monitoring treatment success or disease progression. Also provided is a method to reliably determine an anti-anti-CCR8 antibody in cynomolgus or human plasma. Finally, an anti-murine CCR8 surrogate antibody is disclosed that mimics the unusual half-life of TPP-23411.

The present invention relates to the use of a polypeptide or its antibody binding fragment that can form an antigen-antibody complex in contact with a biological sample obtained from the patient in the preparation of a vascular endothelial cell damage detection reagent or kit; wherein the polypeptide or its antibody binding fragment includes at least two selected from the following groups: alpha enolase protein (ENO1), talin 1 (TLN1), filament protein-A (FLNA), desmosome nexin (AHNAK), desmoglein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90β (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), membrane protrusion protein (MSN). The vascular endothelial cell autoantibodies of the present application can be used to diagnose vascular endothelial cell damage by simply detecting the titer in serum, and have very great clinical application value.

The application discloses a novel coronavirus neutralizing antibody GR46, a detection kit and application thereof, an amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No. 1, and an amino acid sequence of a light chain variable region is shown as SEQ ID No. 2. The application screens the affinity-matured antibody through bioinformatics analysis of a single B cell, combines single-cell RNA sequencing, VDJ rearrangement analysis and somatic hypermutation research, optimizes the antibody screening process, avoids blindness of a traditional method, and improves the accuracy and effectiveness of antibody screening. The neutralizing antibody GR46 provided by the application can specifically combine with a RBD domain of SARS-CoV-2 and a S-Trimer domain of an Omicron mutant strain through the heavy chain and light chain variable regions, realizes broad-spectrum neutralization of SARS-CoV-2 and mutant strains thereof, and the antibody GR46 is significantly superior to other antibodies in the binding activity of S-Trimer and RBD under 2-fold and 300-fold dilution conditions, indicating that the antibody GR46 has high affinity and dilution stability, and is suitable for clinical large-dose administration requirements.

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR58 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR58 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR58 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR58 has high affinity and dilution stability and is suitable for clinical large-dose administration.

Provided is the preparation of a Zika virus non-structural protein NS2A polypeptide and its antibody. A polypeptide is provided, which comprises the amino acid sequence shown in SEQ ID NO.1 or a variant thereof, and the variant has 90% sequence identity with the amino acid sequence shown in SEQ ID NO.1. The present invention for the first time provides a ZIKV NS2A polypeptide and a polypeptide antibody. After the polypeptide is coupled with KLH, a ZIKV NS2A antibody is prepared, and the antibody can be used in Western blot, immunofluorescence experiments and other antigen-antibody recognition experiments.

The present invention discloses camptothecin-class drugs and their antibody conjugates. Based on a comprehensive understanding of ADC-class drugs, the inventors have designed a series of active derivatives of antitumor camptothecin. The designed antitumor molecular compounds have shown good antitumor activity in experiments.

The application discloses an inhibitory antibody or antigen-binding fragment thereof against human OX40, a preparation method and application, and belongs to the technical field of biological immunity. The human-mouse chimeric antibody Y07-L2 and the humanized antibody Y07-C2 prepared by the application have similar EC50 in combination with human OX40, and are similar to the targeted antibody drug KHK-4083 in inhibiting OX40. The heavy chain variable region of the human-mouse chimeric antibody Y07-L2 is shown as SEQ ID NO. 14, and the light chain variable region is shown as SEQ ID NO. 15; the heavy chain variable region of the humanized antibody Y07-C2 is shown as SEQ ID NO. 20, and the light chain variable region of the humanized antibody Y07-C2 is shown as SEQ ID NO. 21; the CDR region of the humanized antibody Y07-C2 is subjected to mutation, and the mutant antibody Y07-C2MH4 and Y07-C2MH4L3 are obviously superior to other antibodies.

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR39 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR39 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR39 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR39 has high affinity and dilution stability and is suitable for clinical large-dose administration.

This invention discloses an anti-ROR1 antibody or its antigen-binding fragment, relating to the fields of biotechnology and medical technology. Ten antibodies with high affinity for the ROR1 protein were screened and can specifically bind to it. This allows for the development of ROR1 detection kits, tumor diagnostic and prognostic kits, as well as antibody-containing pharmaceutical compositions, antibody-drug conjugates, and other antibody-based therapeutic methods. Experimental verification shows that the antibodies provided by this invention have a high killing rate against tumor cells. All of the above antibodies exhibit antibody concentration-dependent cytotoxicity (ADCC), with higher antibody concentrations resulting in better anti-tumor activity. Therefore, the antibodies or their antigen-binding fragments provided by this invention show promising potential for the preparation of tumor therapeutic drugs.

The present invention discloses an anti-Nectin-4 antibody, its antibody-drug conjugate and applications, and the anti-Nectin-4 antibody and its antibody-drug conjugate can be used to treat diseases.

The present invention specifically relates to a monoclonal antibody 8D7, which is directed against the monkeypox virus A35R protein. The present invention first repeats the MPXV A35S gene sequence in tandem via a linker (Gly4Ser)3, and then uses this as an immunogen to screen and obtain the monoclonal antibody 8D7, which is directed against the monkeypox virus A35R protein. The heavy chain of this monoclonal antibody comprises CDR1, CDR2, and CDR3 composed of the amino acid sequences shown in SEQ ID NOs. 1 to 3, and the light chain comprises CDR1, CDR2, and CDR3 composed of the amino acid sequences shown in SEQ ID NOs. 4 to 6. Further experimental studies have revealed that it has good specificity, high binding activity and affinity, and can be used in colloidal gold rapid detection kits, laying the foundation for the detection of monkeypox virus A35R protein.

The present invention belongs to the field of biomedicine, and specifically relates to an siRNA, its antibody conjugate, product and application. The sense strand of the siRNA of the present invention is the sequence shown in SEQ ID NO: 17, and the antisense strand is the sequence shown in SEQ ID NO: 18; the present invention also provides an siRNA antibody conjugate prepared by a site-specific conjugation method, including an antibody, a linker and siRNA, and the siRNA is preferably a modified siRNA; the modified nucleotide is selected from one or more of 2'-position sugar moiety modification, phosphate group modification or nucleotide analogue modification. The siRNA antibody conjugate of the present invention can reduce the expression of DMPK mRNA in human skeletal muscle cells HSKMC and human bladder transitional cell papilloma cells RT4, and has great significance for the treatment of DM1 type myotonic dystrophy disease.